The Latest Breaking News from Abiomed

When Thorsten Siess was in graduate school, he came up with the idea for a heart device that's now been used in hundreds of thousands of patients around the world.

Tighter bank lending and the Fed’s continued fight against inflation will likely push the economy into a recession this year. In this scenario, investors can look to invest in the pharma giant Johnson & Johnson (JNJ), given its financial strength, reliable dividend payments, and solid growth prospects. Read more….

"The addition of Abiomed is an important step in our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech," said CEO Joaquin Duato.

  Abiomed (NASDAQ:ABMD) reported its Q4 earnings results on Thursday, April 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Abiomed (NASDAQ:ABMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that Abiomed will report an earnings per share (EPS) of $1.09.

Abiomed (NASDAQ:ABMD) has observed the following analyst ratings within the last quarter:

Upgrades

With volatility off of recent highs, here's a look at some stocks that have recently dipped and may be worth considering.

According to Benzinga Pro data Abiomed (NASDAQ:ABMD) posted a 19.67% decrease in earnings from Q2. Sales, however, increased by 5.25% over the previous quarter to $261.18 million.